Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
8,718 total articles
Paysign surged after a March 25, 2026 quarter that beat revenue expectations and issued 2026 revenue and earnings guidance. The business is capital-light with strong free cash flow, a modest enterprise value, and visible tailwinds from pharma and plasma verticals. Technical momentum is strong but stretched; this trade idea lays out an entry at $5.7…
Microsoft is trading near pre-COVID valuation multiples (P/E ~22) despite accelerating cloud and AI revenue and $77.4B in free cash flow. The stock looks technically oversold (RSI ~24.7) after a sector-wide derating. This trade targets a mean-reversion to a more constructive mid-cycle multiple: entry $363.50, stop $345.00, target $420.00 over a mid…
Ciena sits at the physical layer that hyperscalers and cloud providers must buy to feed AI models. Strong order backlog, double-digit revenue tailwinds and healthy free cash flow argue for a buy-on-pullback approach. This trade plan targets a measured rebound while acknowledging valuation and execution risks.
Symbotic (SYM) is a leading warehouse automation specialist with a $22B+ backlog, improving margins, and substantial free cash flow. The stock has pulled back into the high-$40s after a post-earnings wobble. I view the current price as a tactical buying opportunity for a mid-term swing trade, sized for disciplined risk management.
ASE (ASX) looks like an actionable long: the stock is digesting a pullback near $20.88 while industry reports point to multi-year growth in high-end packaging and a capacity squeeze for premium solutions. We lay out a mid-term trade with precise entry, stop and target, plus the macro and company-specific catalysts that could re-rate ASE's multiple.
Hillman Solutions is a specialty distributor of fasteners, keys and merchandising solutions showing steady sales growth, free cash flow generation and a valuation that looks reasonable on an EV/EBITDA basis. This trade idea buys a clear recovery narrative — market-share gains in retail merchandising and pricing leverage — with a disciplined stop un…
General Dynamics (GD) just booked a $15.4 billion Navy award for Columbia-class submarines. The contract materially de-risks a large portion of near-term revenue for the Marine Systems business and reinforces free cash flow generation. We outline a tactical long with an entry at $341.00, a stop at $325.00 and a target of $370.00 over a 180 trading-…
Trilogy Metals (TMQ) is a $563M market-cap explorer/developer of the Ambler District in Alaska. The stock is a speculative proxy on executive and federal policy toward domestic critical minerals, plus progress on the company’s 2026 $35M program with South32. This trade idea outlines an entry at $3.25, a stop at $2.60 and a $6.50 target over a 180 t…
Dana Incorporated just lifted its quarterly dividend and doubled its buyback authorization timeline, signaling capital-return confidence while reporting margin improvement. With free cash flow of $298M, EV/EBITDA of 9.7 and room to re-rate toward its 52-week high, Dana looks like a pragmatic tactical long. We lay out an entry, stop and target for a…
Tempus AI presents an actionable long near current levels. Market uncertainty has compressed multiple potential upside drivers into the price; a disciplined entry at $12.50 with a $20 target and $9.50 stop offers a favorable reward-to-risk for a mid-term swing trade. Catalysts include product rollouts, partnership milestones, and improving sell-sid…
State Street is trading at a modest multiple versus earnings and book value despite strong fee revenue trends and record assets under custody. With a current price of $123.44, a trailing EPS near $9.75 and an EV that belies its free cash flow generation, the stock offers a risk/reward profile attractive for a mid-term long. This trade idea lays out…
Willdan Group's combination of improving margins, recurring municipal/utility work and a much-lower valuation base after a 2025 reset creates a compelling mid-term trade. Enter near $76, stop $68, target $110 over a 45-trading-day horizon, with a favorable risk/reward if the company sustains cash flow and backlog conversion.
Barrick Gold looks well positioned to benefit from persistent macro tailwinds for gold and improving fundamentals in base metals. With a clear entry, stop and target, this trade idea favors a long exposure sized to your risk budget for a long-term horizon while acknowledging macro and operational risks.
Cryoport is executing infrastructure and product rollouts that materially lower per-shipment costs and expand addressable capacity for cell and gene therapy logistics. With a market cap below $400M, improving margins, positive ROE/ROA, and a path to near-term breakeven, the stock offers a favorable risk-reward for a position trade. Entry at $7.90, …
Janus International (JBI) looks increasingly attractive at current levels. The stock trades near its 52-week low while the company generates strong free cash flow, carries meaningful cash on the balance sheet, and sits at valuation multiples that imply recovery potential. This trade idea outlines an actionable long with entry, stop, and target alon…
Shake Shack reported 22% revenue growth in Q4 and is guiding to meaningful unit expansion in 2026 while free cash flow is beginning to show positive momentum. At $83.62, the stock trades at an EV/sales of ~2.2 and a lofty P/E near 70 but with improving operating leverage and $1.47B of cash that supports share-price optionality. This trade idea lays…
Universal Music Group appears to have priced in a tougher near-term macro and regulatory backdrop, while the core music-as-a-service business continues to benefit from durable streaming demand, recurring royalty economics and higher-margin publishing and sync opportunities. This trade sets a clear entry, stop and target with a long-term horizon and…
Adyen looks attractive after a period of multiple compression. The business still owns a best-in-class global payments platform, with durable monetization and exposure to secular e-commerce and omnichannel payments growth. This trade outlines a mid-term (45 trading days) swing long with a clear entry, stop and target, plus catalysts that could re-r…
Carlyle Secured Lending appears to have priced a lower, reset dividend into the market. That creates a tactical long opportunity where upside is driven by earnings/NAV verification and improved market sentiment. This trade uses a precise entry, stop and two-tier target plan over a 45- to 180-day horizon.
Exxon Mobil looks set to continue benefiting from a favorable mix of stronger commodity pricing, resilient downstream margins and incremental upstream volumes. This trade idea sizes a mid-term long with clear entry, target and stop levels tied to expected cash-flow resilience and near-term catalysts.
Badger Meter has reset materially from 2025 highs and now offers a buyable mix of recurring software revenue growth, improving margins and a fortress balance sheet. Valuation has come in to a reasonable multiple for a mid-teens growth story; this note lays out an actionable long-term trade with entry, stop and target and the catalysts and risks tha…
Clorox (CLX) offers a sensible trading opportunity for income-oriented investors able to tolerate a medium level of company-specific risk. At roughly $102 per share, the stock yields near 4.8%, trades at a mid-teens P/E, and is sitting close to its 52-week low after a margin squeeze and a retailer inventory reset shaved expected sales and EPS. The …
Uber is getting dinged by headlines around autonomous partnerships and macro noise, but fundamentals - $9.09B free cash flow, a $143.9B market cap, and healthy margins - suggest the stock is mispriced for a 11-45 trading day rebound. This trade idea lays out an entry, stop, targets, catalysts and the specific risks that could derail the setup.
Corcept Therapeutics popped after the FDA approved Lifyorli for platinum-resistant ovarian, fallopian tube and primary peritoneal cancer. The regulatory green light materially reduces binary regulatory risk and creates a clear commercial catalyst. We upgrade to a buy and lay out an actionable trade: entry $38.12, stop $31.00, primary target $60.00 …
Castle Biosciences is set up for a meaningful re-rating as prospective validation of its DecisionDx-Melanoma i31-SLNB test reduces clinical uncertainty for sentinel lymph node management. With a $699.6M market cap, low leverage, positive free cash flow, and oversold technicals, we outline a mid-term trade to capture upside while keeping strict risk…
